IMM2510

Phase 2Small molecule

IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM2510 is one of 90 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerNot yet recruiting

Patients With Advanced Solid TumorsNot yet recruiting

Triple-Negative Breast CancerPhase 2

Not yet recruiting

Patients With Advanced Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

19 2

Eloxatin

Teva

Phase 2

9 3

Tecentriq

Roche

Phase 2

4 4

Camptosar

Pfizer

Phase 2

4 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 6

Erbitux

IImclone

Phase 2

9 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 8

Lazcluze

Johnson & Johnson

Phase 2

1 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

6 10

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Triple-Negative Breast Cancer

NCT06746870

Q3 2029

Phase 1/2Not yet recruiting

Patients With Advanced Solid Tumors

NCT07170787

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Unknown status·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1·NCT05972460·108 enrolled

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1/2·NCT07170787·104 enrolled

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 1·NCT06764836·108 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 2·NCT06746870·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IMM2510. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMM2510 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMM2510. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmuneOnco Biopharmaceuticals (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImmuneOnco Biopharmaceuticals (Shanghai) Inc.

IMM2510

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2029

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News